Oracle's stock has experienced a slight dip recently, retracting from its monthly peak of $250 to approximately $213. Despite this minor setback, the stock maintains a nearly 60% gain from its yearly low, as investor focus shifts to the company's impending earnings report, scheduled for release on Wednesday.
The company's latest financial disclosures showcased a substantial 24% increase in revenue, reaching $17.2 billion. Cloud services emerged as a primary growth driver, with a 44% surge to $8.9 billion. Infrastructure revenue soared by 84% to $4.9 billion, while cloud applications saw a 13% rise to $4 billion.
Despite robust revenue figures, Oracle announced plans to raise an additional $50 billion through a combination of debt and equity. The company had already secured $30 billion and was yet to utilize its at-the-market equity options. By the end of the quarter, Oracle's long-term debt surpassed $124 billion, a significant increase from $85 billion during the same period last year.
According to Benzinga Pro data, analysts anticipate Oracle's Q4 revenue to climb by 20% to $19 billion. If these projections hold, the company's annual revenue would reach $67 billion, marking a 17% year-over-year increase, with forecasts for further growth to $88 billion in the subsequent fiscal year. Analysts maintain a 'buy' rating on the stock, with an average price target of $269, up from the current $213, and some even raising their targets to $284 or $400.
A daily review of ORCL stock reveals a double-bottom formation at $137, with a neckline at $171, signaling a strong bullish reversal. The stock recently formed a golden cross pattern as the 50-day and 200-day Weighted Moving Averages converged. This positive trend began after the stock surpassed the 50% Fibonacci Retracement level.
The most probable outcome is an Oracle stock rebound following the earnings announcement. Should this occur, the immediate target for investors will be $250. A successful breach of this level could pave the way for further gains, potentially reaching $300.